Literature DB >> 16452556

Adopting orphan drugs--two dozen years of treating rare diseases.

Marlene E Haffner1.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16452556     DOI: 10.1056/NEJMp058317

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  46 in total

Review 1.  Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years.

Authors:  M Miles Braun; Sheiren Farag-El-Massah; Kui Xu; Timothy R Coté
Journal:  Nat Rev Drug Discov       Date:  2010-06-07       Impact factor: 84.694

Review 2.  The importance of new companies for drug discovery: origins of a decade of new drugs.

Authors:  Robert Kneller
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 3.  Rare diseases, orphan drugs and their regulation: questions and misconceptions.

Authors:  Erik Tambuyzer
Journal:  Nat Rev Drug Discov       Date:  2010-11-09       Impact factor: 84.694

4.  Policy alternatives for treatments for rare diseases.

Authors:  Abbas H Panju; Chaim M Bell
Journal:  CMAJ       Date:  2010-07-12       Impact factor: 8.262

5.  Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.

Authors:  Carl Rudolf Blankart; Tom Stargardt; Jonas Schreyögg
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

6.  Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.

Authors:  Bas C Stunnenberg; Joost Raaphorst; Hans M Groenewoud; Jeffrey M Statland; Robert C Griggs; Willem Woertman; Dick F Stegeman; Janneke Timmermans; Jaya Trivedi; Emma Matthews; Christiaan G J Saris; Bas J Schouwenberg; Gea Drost; Baziel G M van Engelen; Gert Jan van der Wilt
Journal:  JAMA       Date:  2018-12-11       Impact factor: 56.272

7.  Orphan products: an emerging trend in drug approvals.

Authors:  Timothy Coté; Aditya Kelkar; Kui Xu; M Miles Braun; M Ian Phillips
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

8.  Harnessing the Digital Exhaust: Incorporating wellness into the pharma model.

Authors:  Justin M Wright; Graham B Jones
Journal:  Digit Biomark       Date:  2018-04-11

Review 9.  [Orphan drugs : New opportunities for the treatment of rare diseases].

Authors:  M Beck
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

Review 10.  Garrod's Croonian Lectures (1908) and the charter 'Inborn Errors of Metabolism': albinism, alkaptonuria, cystinuria, and pentosuria at age 100 in 2008.

Authors:  Charles R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-10-12       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.